Mr. Sheridan has served on our board of directors since June 2019 and as our President and Chief Executive Officer since March 2019. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining us, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan serves as a director of Acutus Medical, Inc. (Nasdaq: AFIB), an arrhythmia management company. Mr. Sheridan holds a BS in Chemistry from the University of West Florida and an MBA from Boston University.
David Berger has served as our Executive Vice President and Chief Operating Officer since February 2022 and is responsible for the Company’s manufacturing, supply chain, quality, regulatory and clinical functions. He previously served as our Chief Business Operations and Compliance Officer since November 2020, as our Executive Vice President, Chief Legal and Compliance Officer since April 2019, and as General Counsel since August 2013. From January 2008 until August 2013, Mr. Berger was employed at Senomyx, Inc., a taste science company, where he most recently served as Senior Vice President and General Counsel. From April 2003 until October 2007, Mr. Berger was responsible for all commercial aspects of legal affairs at Biosite Incorporated, Biosite, a provider of medical diagnostic products, most recently serving as Vice President, Legal Affairs. Previously, Mr. Berger was an attorney at Cooley Godward LLP and Amylin Pharmaceuticals, Inc. Mr. Berger holds a BA in Economics from the University of California, Berkeley and a JD from Stanford Law School.
Tom Fox was appointed Chief Human Resources Officer in August 2023. From August 2020 to July 2023, he served as Senior Vice President, Human Resources and Organizational Development. From August 2017 to July 2020, he served as Vice President, Human Resources. Prior to this, he served as Senior Director of our Human Resources Department. Mr. Fox has more than 20 years of experience in Human Resources management. Prior to joining Tandem, Mr. Fox served as Director of Human Resources for the Oncology-Genoptix Division of Novartis Pharmaceuticals. Before that, he held various HR leadership positions including Director of Human Resources for the West Division of BDO, USA LLP; Director of HR Client Services for Option One Mortgage Company (a subsidiary of H&R Block Corp.) and Director of Labor and Employee Relations at The Walt Disney Company, Disneyland Resort. Mr. Fox began his career at Chevron Corporation and holds a BS in Business Administration from California State University, Fresno and a MS in Labor Relations and Human Resources Management from Michigan State University.
Elizabeth Gasser has served as our Executive Vice President and Chief Strategy Officer since June 2021 and is responsible for the Company’s strategy, corporate development, product management and competitive intelligence functions. She previously served as our Executive Vice President, Strategy and Corporate Development since January 2020. Prior to joining our Company, Ms. Gasser served from June 2017 as an independent adviser providing strategic and corporate development solutions to boards and executive teams. From January 2016 to June 2017 she was Vice President of Corporate Strategy at QUALCOMM Technologies, Inc. (QTI), a subsidiary of QUALCOMM Incorporated (Nasdaq: QCOM), a global leader in the development and commercialization of technologies and products used in mobile devices and other wireless products. Prior to that, from November 2012 to January 2016 she was Vice President of Strategic Development at QTI, after serving in other strategic related roles of increasing responsibility beginning in 2006. Ms. Gasser holds a BA and an MA in Economics from the University of Cambridge.
Brian Hansen has served as our Executive Vice President and Chief Commercial Officer since February 2016. Prior to joining our Company, Mr. Hansen served from September 2014 as Chief Commercial Officer of Adaptive Biotechnologies Corp. From May 2013 to September 2014, Mr. Hansen served as Head of Commercial, Sales and Marketing, of Genoptix, a Novartis Company. From December 2005 to February 2013, he served in various roles of increasing responsibility at Gen-Probe, Inc., a medical diagnostics company, most recently serving as Senior Vice President, Global Sales and Services from January 2012 to February 2013. Mr. Hansen received a BS in Business Administration from the University of Missouri-Columbia, and an MBA from the School of Business at San Diego State University.
Jim Leal was appointed Chief Manufacturing Officer in April 2023. From August 2017 to April 2023, he served as Senior Vice President, Operations. Prior to this, he served as Vice President, Operations. Mr. Leal has more than 25 years of manufacturing and engineering experience. Prior to joining Tandem, Mr. Leal was the Vice President of Manufacturing and Field Support for Volcano Corporation and held Director Roles with CardioNet, Inc. and Digirad Corporation. He held Senior Engineering roles with FlipChip Technologies and Hughes Aircraft Company. Jim has won several awards including a Hughes Aircraft Doctoral and Masters Fellowship and was a recognized nominee for Most Promising Hispanic Engineer of the Year Award. Mr. Leal is a published author and patent holder. He is a University of Arizona graduate with a PhD in Materials Science and Engineering.
Susan Morrison has served as an Executive Vice President since December 2017 and as our Chief Administrative Officer since September 2013, and is responsible for the Company’s investor relations, corporate communications, program management, human resources and facilities functions. Prior to that time she served in successive leadership positions for our Company since November 2007, including Vice President, Human Resources, Corporate and Investor Relations and Director, Corporate and Investor Relations. Prior to joining our Company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.
Dr. Jordan Pinsker joined us as Vice President and Medical Director in April 2021. He is a leading pediatric endocrinologist and prominent thought leader in artificial pancreas research. Dr. Pinsker joined Tandem from Sansum Diabetes Research Institute in Santa Barbara, California, where he served as the Director of Artificial Pancreas Technology since 2018. In his role at Sansum, he was a lead investigator in numerous clinical trials on automated insulin delivery systems, including Basal-IQ® and Control-IQ™ technology. Prior to this, he was Chief of Pediatric Endocrinology at Tripler Army Medical Center in Hawaii. Dr. Pinsker served as a physician in the United States Army in both Active Duty and in the California Army National Guard for more than 20 years. He completed a combined seven-year BS/MD program with Union College and Albany Medical College in New York. Dr. Pinsker is board certified in Clinical Informatics, Pediatric Endocrinology and General Pediatrics.
Leigh Vosseller has served as our Executive Vice President, Chief Financial Officer, and Treasurer since June 2018, and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is our principal financial and accounting officer. She joined us as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Prior to that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011, after initially joining Genoptix in 2008. Prior to that she held a senior finance position at Biosite where she played a key role in developing the financial and administrative infrastructure for international expansion. Since January 2021, Ms. Vosseller has served as a director and chair of the finance committee of Girls Inc. of San Diego County, a non-profit organization that provides STEM-focused, research-based programming to underserved girls in the community. Ms. Vosseller is a certified public accountant (inactive) and holds a B.S. in Accounting from Missouri State University.